Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;12(12):28-34.
Epub 2019 Dec 1.

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

Corinna E Psomadakis  1 , George Han  1
Affiliations
Review

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

Corinna E Psomadakis et al. J Clin Aesthet Dermatol. 2019 Dec.

Abstract

Psoriasis and atopic dermatitis represent two of the most common skin conditions seen by both primary care and specialist dermatology. The prevalence of psoriasis in North America is 2 to 4 percent, and it is estimated to cost more than $3 billion per year to treat this condition. Atopic dermatitis has an estimated 15 to 30 percent lifetime prevalence in children and an 8 to 10 percent lifetime prevalence in adults. Both diseases have a significant impact on patient quality of life, as well as associated psychological, social, and economic consequences. While systemic therapies are available for both, the majority of patients with each condition are treated with topical therapies alone, with varying degrees of efficacy and patient satisfaction. As such, there is both need and an incentive to develop new treatments for these two conditions. In this paper, we review new and emerging topical therapies for psoriasis and atopic dermatitis.

Keywords: Benvitimod; Crisaborole; Eucrisa; GATA-3; Genador; JAK inhibitor; JAKSTAT; PDE4 inhibitor; PH-10; Pefcalcitol; Psoriasis; Tofacitinib; atopic dermatitis; eczema; enstilar; hydroxypropyl-chitosan; phosphodiesterase-4 inhibitor; retinoids; sernivo; steroid; tazarotene; topical; vitamin D analog.

PubMed Disclaimer

Conflict of interest statement

FUNDING:No funding was provided for this study. DISCLOSURES:Dr. Han has consulted for Regeneron, Sanofi Genzyme, Pfizer, Sun, and Janssen. Dr. Psomadakis has no conflicts of interest relevant to the content of this article.

References

    1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. - PubMed
    1. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407. 3 Pt 1. - PubMed
    1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–546. - PubMed
    1. Taraska V, Tuppal R, Olesen M et al. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20(1):44–51. - PMC - PubMed
    1. Stein Gold L, Lebwohl M, Menter A et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15(8):951–957. - PubMed

LinkOut - more resources